The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design

Seung Ho Kang, Chul Ahn

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Abstract

A main purpose of Phase I cancer clinical trials is to identify the maximum tolerated dose (MTD) of a new agent for experimentation in Phase II and III studies. The continual reassessment method has been shown to be superior to the standard design. However, in practice, the standard design has still been widely used. Therefore, it is important to investigate the performance of the standard design accurately. In this paper, we develop an algorithm to compute the exact distribution of the recommended dose level in the standard design. The algorithm is a better tool than simulation in the investigation of the operating characteristics of the standard design, because it does not involve any sampling error and computing time is much shorter than simulation. With the algorithm, the expected toxicity rate at the MTD in the standard design is investigated extensively for some dose-toxicity curves in a certain range.

Original languageEnglish (US)
Pages (from-to)1189-1199
Number of pages11
JournalDrug Information Journal
Volume35
Issue number4
DOIs
StatePublished - Jan 1 2001

Keywords

  • Cancer
  • Continual reassessment method
  • Dose finding studies
  • Toxicity

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Drug guides
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'The expected toxicity rate at the maximum tolerated dose in the standard phase I cancer clinical trial design'. Together they form a unique fingerprint.

Cite this